Latest Stock Buy or Sell? Make More Informed Decisions!
Today, Bruce Murray and The Panic-Proof Portfolio (Stockchase Research) commented about whether HRTG-N, IMO-T, CGI-T, AC-T, LNR-T, LLY-N, META-Q, ORCL-N, CLS-T, SHOP-T, EIF-T, MRK-N, CVE-T, MDI-T, DBM-T, CPX-T, MFC-T, AZN-N, GOOG-Q, AC-T, BLK-N, DNTL-T, WELL-T, BCE-T, PRL-T, TFII-T, X-T, PFE-N are stocks to buy or sell.
- Page 3/3
- Next Page
Classic value stock. Buying back stock. $10 EPS, so it's selling at 4.5x earnings. Everything they make is under USMCA. No one can make what they do. High-end, specialized agricultural products. Agriculture and autos are both down; autos are about to turn up, and agricultural should too. Yield is 2.09%.
(Analysts’ price target is $65.83)
Canada's largest airline just announced resumption of service from the nation's capital to London UK -- signs of global schedule shuffles and adjusting to declining US bookings. We like that debt is being aggressively retired and shares bought back. It trades at 6x earnings, 2x book and supports a robust 108% ROE. We recommend setting a stop at $9, looking to achieve $18 -- upside potential of 28%. Yield 0%
(Analysts’ price target is $23.42)CGI holds investments in a well diversified portfolio including NVIDIA, Franco-Nevada, and CP Kansas City rail. It trades at 2x earnings, under book value and supports a 23% ROE. It's dividend is backed by a payout ratio under 10% of cash flow. We recommend setting a stop-loss at $27, looking to achieve $42 -- upside potential of 26%. Yield 3.0%
(Analysts’ price target is $169.00)Markets have factored in lower oil prices into the share price, but as the company is also a refiner, its downstream segment will benefit from lower feedstock costs. It trades at 12x earnings, under 2x book and supports a ROE of 21%. The company will announce latest financial results today -- we'll see if they are able to continue growing cash reserves. We recommend setting a stop-loss at $67, looking to achieve $103 -- upside potential of 16%. Yield 2.9%
Plethora of ideas. Part of the story on cancer. Weight-loss drug is in the lead, and a pill instead of injection is the ultimate goal. Earnings from weight loss will double in 3 years, and then they still have all the other drugs in the pipeline. Yield is 0.70%.
(Analysts’ price target is $996.37)